Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PYC-003 in Healthy Adults and ADPKD Patients
NCT06714006Phase 1Recruiting
- Sponsor
- PYC Therapeutics
- Start
- Apr 2025
- Primary completion
- Nov 2028
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of PYC-003 in autosomal dominant polycystic kidney disease (ADPKD) (4 arms), sponsored by PYC Therapeutics. Primary endpoints: Number of participants experiencing treatment emergent adverse events up to 98 weeks, Changes from baseline in vital signs up to 98 weeks and 9 more. Started Apr 2025; status: recruiting.
02
Drugs
PYC-003
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT06714006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06714006.